EFDA (Ethiopia)

EFDA (the Ethiopian Food and Drug Authority) is the Federal Democratic Republic of Ethiopia's autonomous federal regulatory agency responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + traditional medicines (including the rich Ethiopian + Habesha + Oromo traditional medicine tradition) + cosmetics + food + tobacco + drugs of abuse + healthcare-facility licensing coordination. EFDA was established under Food and Medicine Administration Proclamation 1112/2019 (the current organic law, signed into law January 2019 + operational October 2019), which succeeded EFMHACA (Ethiopian Food, Medicine and Healthcare Administration and Control Authority) under Proclamation 661/2009 + DACA (Drug Administration and Control Authority) under Proclamation 176/1999. The 2019 reform under Proclamation 1112/2019 separated healthcare-facility regulation (transferred to the Ministry of Health Quality Directorate) from product regulation (retained at EFDA) — narrowing EFDA's scope to food, medicines, devices, tobacco + drugs of abuse + sharpening its regulatory focus.

EFDA's organisational structure includes:

• Director General — chief executive appointed by the Prime Minister of Ethiopia; serves a 5-year renewable term.
• Management Board — chaired by the State Minister for Health + comprising MoH, Ministry of Industry, Ministry of Trade & Regional Integration, Ministry of Agriculture, Ministry of Finance, Ethiopian Pharmaceuticals Manufacturing Association (EPMA), Ethiopian Medical Association + civil-society representatives.
• Deputy Director General for Medicines, Medical Devices & Cosmetics Regulation — oversees Medicines Authorisation + Medical Devices + Cosmetics + Traditional Medicines Directorates.
• Deputy Director General for Food, Tobacco & Veterinary-Origin Foods Regulation — oversees Food Safety + Tobacco + Veterinary-Origin Foods Directorates.
• Deputy Director General for Inspection, Enforcement & Port Health — oversees GMP/GDP Inspectorate + Enforcement + Port Health + Anti-Counterfeit Directorates.
• Medicines Authorisation Directorate — drug + biological + vaccine + biosimilar + biotechnology + traditional-medicine registration.
• Medical Devices & IVD Authorisation Directorate — Class A-D devices + IVDs + cosmetics registration + Authorised Representative oversight.
• GMP / GDP Inspectorate Directorate — Ethiopian + foreign manufacturer + distributor GMP/GDP inspections.
• Pharmacovigilance & Clinical Trials Directorate — adverse-event surveillance + clinical-trial authorisation + ESAVI + Med Safety App Ethiopia.
• NFBMQCL (National Food, Beverage & Medicine Quality Control Laboratory) — WHO-prequalified pharmaceutical QC laboratory + food + beverage testing; ISO/IEC 17025 accredited.
• Port Health & Anti-Counterfeit Directorate — port-of-entry inspections + counterfeit-medicines enforcement + cross-border IGAD coordination.
• Tobacco Control Directorate — Tobacco Control Proclamation 1112/2019 + WHO FCTC implementation.
• International Affairs & Harmonisation Directorate — WHO + AMA + AMRH + IGAD + WHO PQ CRP + bilateral cooperation.

EFDA is distinct from + complementary to: the Ministry of Health (MoH, policy + healthcare-facility regulation post-2019 reform); the Ethiopian Pharmaceutical Supply Service (EPSS, public-sector pharmaceutical procurement + supply chain for federal health programmes); the Ethiopian Public Health Institute (EPHI, public-health surveillance + reference-laboratory functions including the National Influenza Centre); the Ministry of Agriculture (veterinary medicines + animal-origin foods primary authority, with EFDA coordination at port-of-entry); the Ethiopian Standards Agency (ESA, voluntary standards); the Ethiopian Conformity Assessment Enterprise (ECAE, conformity assessment + product certification); + the Ethiopian Pharmaceuticals Manufacturing Association (EPMA, ~25 Ethiopian pharmaceutical manufacturers including the largest sub-Saharan African insulin + vaccine + ARV producers).

Legal foundations are Food and Medicine Administration Proclamation 1112/2019 (organic law); Pharmaceutical Manufacturing Directive 822/2014 + EFDA Directive updates (current Ethiopian GMP framework substantively aligned with WHO TRS 986 Annex 2 + PIC/S + ICH Q7); Medical Devices Directive 868/2015 (Ethiopian medical-devices + IVD framework substantively aligned with GHTF/IMDRF); Pharmacovigilance Directive 814/2014 (Ethiopian pharmacovigilance framework substantively aligned with ICH E2); Clinical Trials Directive 845/2014 (Ethiopian GCP framework substantively aligned with ICH E6(R2)); Cosmetics Directive 869/2015; Tobacco Control Proclamation 1112/2019 (incorporated into EFDA organic law) + WHO Framework Convention on Tobacco Control (FCTC) implementation; Food Safety + Hygiene Directives + Codex Alimentarius implementation; + the substantial body of EFDA technical guidelines + Common Technical Documents.

EFDA achieved WHO Global Benchmarking Tool (GBT) Maturity Level 3 (ML3) for medicines in December 2022 — the second sub-Saharan African medicines regulator to reach ML3 after Tanzania TMDA (December 2018), ahead of Ghana FDA + Nigeria NAFDAC (both ML3 candidate). EFDA ML3 designation reflects a stable, well-functioning + integrated regulatory system for medicines + provides foundation for WHO Listed Authority designation + accelerated WHO PQ CRP reliance + AMRH co-Reference Authority leadership. EFDA is a WHO Listed Authority candidate + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Moroccan DMP + an AMA (African Medicines Agency) Technical Committee participant + an IGAD (Intergovernmental Authority on Development) regulatory-harmonisation partner alongside Kenya PPB + Uganda NDA + Djibouti + Somalia + South Sudan DFDA + Sudan NMPB.

Ethiopian pharmaceutical regulation operates under a layered framework of Proclamations + EFDA Directives + technical guidelines:

• Food and Medicine Administration Proclamation 1112/2019 — organic law establishing EFDA + scope + powers; succeeded EFMHACA Proclamation 661/2009 + DACA Proclamation 176/1999.
• Pharmaceutical Manufacturing Directive 822/2014 + EFDA updates — current Ethiopian Good Manufacturing Practice Guidelines substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP Guide + ICH Q7.
• Pharmaceutical Distribution Directive 823/2014 — Ethiopian Good Distribution Practice substantively aligned with WHO + EU GDP.
• Medicines Registration Directive 821/2014 + EFDA updates — Ethiopian drug + biological + vaccine registration framework substantively aligned with WHO + ICH CTD.
• Medical Devices Directive 868/2015 — Ethiopian medical-devices + IVD framework with Class A-D risk-based classification substantively aligned with GHTF/IMDRF + AMRH-MDH (Medical Devices Harmonisation).
• Pharmacovigilance Directive 814/2014 — Ethiopian pharmacovigilance framework substantively aligned with ICH E2A-E + WHO PIDM.
• Clinical Trials Directive 845/2014 — Ethiopian Good Clinical Practice substantively aligned with ICH E6(R2) + WHO TRS 850.
• Cosmetics Directive 869/2015 — Ethiopian cosmetics framework substantively aligned with EAC Cosmetics Harmonisation + ASEAN Cosmetics Directive structure.
• Tobacco Control Proclamation 1112/2019 (incorporated) — WHO FCTC implementation including graphic health warnings + advertising bans + smoke-free public spaces.
• Traditional Medicines Directive — Ethiopian + Habesha + Oromo + Amhara traditional-medicine registration framework recognising rich Ethiopian ethnobotanical tradition.
• Food Safety + Hygiene Directives + Codex Alimentarius implementation — Ethiopian food regulation harmonised with Codex.
• Anti-Counterfeit Medicines Directive — substantive cooperation with Ethiopian Federal Police + Interpol + WHO Global Surveillance & Monitoring System for substandard + falsified medicines.
• IGAD Regulatory Harmonisation Resolutions — emerging IGAD pharmaceutical-harmonisation framework across Ethiopia + Kenya + Uganda + Djibouti + Somalia + South Sudan + Sudan + Eritrea.

NFBMQCL (the National Food, Beverage & Medicine Quality Control Laboratory) is EFDA's central pharmaceutical + food + beverage quality-control laboratory in Addis Ababa. NFBMQCL is one of the few WHO-prequalified pharmaceutical QC laboratories in sub-Saharan Africa (WHO PQ-Lab since 2018), joining a small group including South Africa's National Control Laboratory + selected African Pharmacopoeia + WHO Collaborating Centres. NFBMQCL WHO PQ-Lab designation provides Ethiopia with direct regulatory laboratory capacity + reduces dependence on foreign analytical services + supports AMRH + AMA reliance frameworks.

• WHO Prequalification of Quality Control Laboratories Status — NFBMQCL holds WHO PQ-Lab status since 2018; provides Ethiopia with WHO-recognised pharmaceutical QC capacity for WHO PQ + EFDA regulatory testing + Global Fund + Gavi + UNICEF procurement support.
• ISO/IEC 17025 Accreditation — NFBMQCL is ISO/IEC 17025 accredited (ENAO — Ethiopian National Accreditation Office) across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing + food + beverage testing.
• AMRH Regional Reference Laboratory — NFBMQCL serves AMRH-coordinated regional reference-laboratory functions for sub-Saharan African medicines QC capacity.
• Vaccine lot release — NFBMQCL conducts vaccine lot-release testing for EFDA + Ethiopian EPI + supports vaccine releases for Ethiopian + African vaccine programmes.
• Pharmaceutical pre-registration + post-market testing — NFBMQCL conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for EFDA.
• Counterfeit-medicine forensics — NFBMQCL provides forensic analytical support for EFDA Port Health + Anti-Counterfeit Directorate + Ethiopian Federal Police investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — NFBMQCL hosts AMRH + AMA capacity-building programmes + training for sub-Saharan African pharmaceutical analysts; serves as WHO Collaborating Centre for pharmaceutical analytical training.
• GMP Inspectorate base — NFBMQCL provides scientific + technical support for EFDA GMP inspections of Ethiopian + foreign manufacturing facilities.
• Food + beverage testing — NFBMQCL conducts food + beverage + cosmetic + traditional-medicine analytical testing supporting EFDA food + cosmetic regulation.
• COVID-19 + pandemic response — NFBMQCL was central to Ethiopia's COVID-19 response including PCR support + medicines quality testing + vaccine lot release for AVAT + COVAX procured products.

EFDA medical-device + IVD regulation operates under Medical Devices Directive 868/2015 with a Class A-D risk-based framework substantively aligned with GHTF/IMDRF + AMRH-MDH (Medical Devices Harmonisation). Foreign manufacturers must appoint an Ethiopian Authorised Representative.

• Risk-based Classification (Class A / B / C / D) — substantively aligned with GHTF/IMDRF + AMRH-MDH; IVDs classified under same Class A-D framework with IVD-specific rules.
• Ethiopian Authorised Representative — Ethiopia-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + EFDA regulatory interface.
• ISO 13485:2016 — recognised by EFDA as QMS evidence framework; Ethiopian-specific overlay required including Ethiopian quality records + Authorised Representative QMS interface.
• Reliance pathways — EFDA accepts CE Mark + FDA 510(k) + Health Canada + TGA + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier + accelerates review.
• AMRH Medical Devices Harmonisation — EFDA participates in AMRH-MDH work-streams; reliance + harmonised technical-file requirements progressively expanding across African Member States.
• Post-market materiovigilance — EFDA operates medical-device adverse-event reporting through the Ethiopian Materiovigilance System; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Directive 869/2015 require Cosmetic Notification + Amharic + English labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Ethiopian UDI — EFDA is progressively implementing UDI requirements substantively aligned with FDA UDI + IMDRF UDI guidance; Ethiopian-specific overlay applies.
• Importation Permit — EFDA Importation Permit required in addition to product registration for foreign-manufactured devices entering Ethiopia.

EFDA operates the Ethiopian Pharmacovigilance Programme under Directive 814/2014. Ethiopia is a long-standing WHO Programme for International Drug Monitoring (PIDM) member (since 2008) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). Med Safety App Ethiopia (Amharic + Oromo + Tigrinya + English) was adopted from Kenya PPB + Uganda NDA models in 2022.

• Ethiopian Pharmacovigilance Programme — coordinated national pharmacovigilance programme with effector centres in major teaching hospitals (Tikur Anbessa, Black Lion, St. Paul's, Jimma, Gondar, Hawassa, Mekelle) + EPHI + EPSS + Marketing Authorisation Holders.
• WHO PIDM Long-standing Member — Ethiopia is a long-standing WHO PIDM member (since 2008) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Med Safety App Ethiopia — multilingual (Amharic + Oromo + Tigrinya + English) ADR-reporting smartphone application adopted from Kenya PPB + Uganda NDA models in 2022; substantially expanded ADR reporting volume + accessibility.
• Online ADR Reporting — EFDA operates online ADR reporting via the EFDA Pharmacovigilance Portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — EFDA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); EFDA-specific submission timeline.
• Risk Management Plans (RMP) — EFDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — EFDA operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + malaria + COVID-19 vaccines + biologicals; substantial donor-funded surveillance via PEPFAR + Global Fund + Gavi.
• ESAVI (Events Supposedly Attributable to Vaccination + Immunization) — Ethiopian vaccine adverse-event surveillance aligned with WHO methodology; central to EPI + COVID-19 vaccine safety monitoring.
• Materiovigilance + Cosmetovigilance — EFDA operates parallel materiovigilance for medical devices + cosmetovigilance for cosmetic adverse events.

• WHO Maturity Level 3 (ML3) for Medicines — achieved December 2022 + second sub-Saharan African ML3 medicines NRA after Tanzania TMDA (2018); ahead of Ghana FDA + Nigeria NAFDAC.
• WHO Listed Authority Candidate — EFDA is a WHO Listed Authority candidate based on ML3 designation + active WHO PQ CRP participation.
• WHO PQ CRP Participating Authority — EFDA is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab — NFBMQCL is a WHO-prequalified pharmaceutical QC laboratory since 2018; one of few in sub-Saharan Africa.
• AMRH co-Reference Authority — EFDA is an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Moroccan DMP.
• AMA Technical Committee Participant — EFDA participates in African Medicines Agency (AMA) Technical Committees under AU Decision Assembly/AU/Dec.857(XXXVII) + Kigali HQ coordination; positioned to provide reliance assessments for AMA-coordinated submissions.
• IGAD Regulatory Harmonisation Partner — EFDA is a founding partner of the emerging IGAD (Intergovernmental Authority on Development) pharmaceutical regulatory-harmonisation framework alongside Kenya PPB + Uganda NDA + Djibouti + Somalia + South Sudan DFDA + Sudan NMPB + Eritrea.
• ICH Observer Candidate — EFDA is positioned for ICH Observer status; ICH guidelines extensively implemented in Ethiopian regulatory practice.
• IMDRF Affiliate Candidate — EFDA is positioned for IMDRF Affiliate status + draws on IMDRF guidance for medical-device regulation.
• Bilateral MoUs — EFDA holds MoUs with US FDA + EMA + MHRA + Health Canada + Indian CDSCO + Chinese NMPA + Japanese PMDA + Korean MFDS + Egyptian EDA + Moroccan DMP + South African SAHPRA + Kenyan PPB + Tanzanian TMDA + Ugandan NDA + Rwandan FDA + Nigerian NAFDAC.
• PIC/S Pre-Accession Pathway — EFDA is on PIC/S Pre-Accession pathway; GMP framework substantively aligned with PIC/S GMP Guide + WHO TRS 986 Annex 2 + ICH Q7.
• Global Fund + Gavi + PEPFAR + UNICEF — EFDA coordinates extensively with Global Fund + Gavi + PEPFAR + UNICEF for donor-procured medicines + vaccines + diagnostics quality assurance + reliance.
• AVAT + COVAX coordination — EFDA was central to Ethiopia's AVAT (Africa Vaccine Acquisition Trust) + COVAX coordination for COVID-19 vaccines including NFBMQCL lot-release support.
• ICDRA + AVAREF participation — active International Conference of Drug Regulatory Authorities + African Vaccine Regulatory Forum (AVAREF) participant.

• Ethiopian Authorised Representative not properly designated — application rejected at EFDA intake or post-approval compliance failure.
• Amharic + English labelling deficiencies — Amharic + English labelling required (multilingual Ethiopia has Amharic federal working language + English official documentation language + ~80 local languages including Oromo + Tigrinya + Somali + Sidama); many applicants provide insufficient Amharic-language Patient Information Leaflet.
• GMP Directive 822/2014 gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Ethiopia-specific EFDA Directive 822/2014 clarifications + Ethiopian quality records.
• Ethiopian climate-zone stability data missing — Ethiopia spans Climate Zone IVa (hot humid lowlands + Awash Valley) + Climate Zone II (temperate central highlands) + high-altitude Addis Ababa (~2,355m above sea level); many applicants provide insufficient zonal-specific stability data.
• Bioequivalence centres + biowaiver — EFDA Biowaiver Guidance provides BCS-based biowaivers + applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated EFDA CRP review (90-day target); under-utilised by many applicants.
• AMRH / AMA reliance not leveraged — AMRH co-Reference Authority + AMA Technical Committee reliance pathways under-utilised; provides substantial acceleration for African-Reference-Authority-assessed products.
• Vital + Essential Medicines accelerated pathway not leveraged — accelerated registration for EML-listed + vital medicines + EPSS procurement-priority products under-utilised; 90-120 working day target.
• MoH healthcare-facility scope confusion — pharmacy practice + pharmacy premises licensing + healthcare-facility licensing sit with MoH Quality Directorate post-2019 reform, not EFDA; EFDA focuses on product regulation + manufacturer/distributor inspection.
• Ministry of Agriculture jurisdictional split — veterinary medicines + animal-origin foods sit primarily with Ministry of Agriculture, with EFDA port-of-entry coordination only; avoid filing veterinary applications to EFDA.
• Traditional Medicine pathway not leveraged — distinctive Ethiopian traditional-medicine registration pathway under-utilised; recognises rich Ethiopian + Habesha + Oromo + Amhara ethnobotanical tradition + EPHI traditional-medicine research.
• Variations strategy not planned — variations procedure substantively similar to WHO but with Ethiopia-specific timelines + fee structure + Amharic-language requirements.
• Renewal timing missed — 5-year registration renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial NRERC + Directive 845/2014 steps — Ethiopian clinical trials require EFDA CTA + NRERC (National Research Ethics Review Committee) approval; sponsors sometimes overlook NRERC recognition + community-engagement requirements for Ethiopian rural + pastoralist populations.
• Pharmacovigilance + Med Safety App Ethiopia gaps — EFDA Directive 814/2014 requirements substantively similar to ICH E2 but with Ethiopia-specific Pharmacovigilance Portal submission + multilingual ADR reporting requirements.

V5 Ultimate provides the operational infrastructure Ethiopian + foreign-supplier sites need for Proclamation 1112/2019 + Directive 822/2014 GMP + EFDA Medical Devices framework + AMRH + AMA + WHO PQ CRP + IGAD + Ethiopian Pharmacovigilance Programme readiness.

• EFDA Directive 822/2014 GMP control framework — WHO TRS 986 Annex 2 + PIC/S + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Ethiopia-specific clarifications + Ethiopian climate-zone IVa/II + high-altitude stability monitoring.
• EFDA drug-registration packaging — Ethiopian CTD-aligned dossier structure with Ethiopia Module 1 specifics + Module 3 stability + Amharic + English Patient Information Leaflet + Authorised Representative declarations + Directive 821/2014 framework.
• AMRH / AMA workflow — AMRH co-Reference Authority + AMA Technical Committee packaging for joint assessment + reliance across African Member States.
• WHO PQ CRP workflow — EFDA-as-CRP-participating-authority packaging with reduced dossier + accelerated EFDA review (90-day target).
• IGAD workflow — emerging IGAD pharmaceutical-harmonisation packaging across Ethiopia + Kenya + Uganda + Djibouti + Somalia + South Sudan + Sudan.
• Vital + Essential Medicines accelerated workflow — EML-listed + vital + EPSS-procurement-priority product packaging with 90-120 working day accelerated review.
• Ethiopian Authorised Representative workflow — foreign-manufacturer Authorised Representative designation + role-management + Ethiopia-specific post-market surveillance + EFDA interface.
• Ethiopian clinical-trial workflow — Directive 845/2014 GCP + NRERC + EFDA-registered investigator + Ethiopian SUSAR reporting + community-engagement for Ethiopian rural + pastoralist populations.
• EFDA Pharmacovigilance + Med Safety App Ethiopia integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + multilingual (Amharic + Oromo + Tigrinya + English) ICSR + Ethiopian Pharmacovigilance Programme coordination + VigiBase upload + Risk Management Plan packaging + ESAVI vaccine adverse-event reporting + Med Safety App Ethiopia integration.
• Medical-device + cosmetic + IVD workflow — Directive 868/2015 + 869/2015 dossier packaging + Class A-D classification + ISO 13485 + Authorised Representative + post-market materiovigilance + cosmetovigilance.
• EFDA Variations workflow — variations classification + EFDA procedure + Ethiopian packaging.
• Renewal workflow — 5-year registration renewal window tracking + EFDA procedure packaging.
• Traditional Medicine workflow — Ethiopian + Habesha + Oromo + Amhara traditional-medicine product packaging with safety + quality + traditional-use evidence + EPHI coordination.
• AMRH + AMA + IGAD regional bridging — for companies operating across Africa, V5 surfaces EFDA + SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Moroccan DMP harmonised dossier-element reuse alongside national-specific extensions.